renovarobio.com - RENB Operating profit EBITDA
The investment attractiveness of Renovaro Inc. (RENB) is based on long-term grants and patent protection for its AI modules. The absolute EBITDA volume demonstrates cash flow resilience, where determines the latest valuation metric. Precision medicine via biomarkers enables the detection of oncology at early stages. The stability of the R&D core is ensured by stock option incentives for leading oncologists and virologists.
Renovaro (RENB) - metric breakdowns and financial figures
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
- earnings and market ratios statistics:
RENB - Net Profit|Projected Future Earnings Renovaro Inc.|RENB - Price to Earnings Ratio|Future Price to Earnings Multiple Renovaro Biosciences|RENB - Price/Earnings to Growth Ratio|Company Value to EBITDA Renovaro|RENB - Operating profit before deduction of amortization|Earnings per share for the trailing year Renovaro|RENB - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months renovarobio.com|RENB - Earnings per share growth in current year|Projected earnings per share growth rate for next year Renovaro Inc.
Analysis of all company metrics:Renovaro Inc. - RENB
This indicator determines the investment stability of Renovaro Inc. (RENB) by measuring net cash flow from operating activities, excluding accounting adjustments and one-time write-offs. By analyzing this EBITDA chart, an investor can see the real operational return, which is currently offset by high R&D costs and the implementation of AI diagnostics, confirming a period of intensive reserve spending for the company.
Competitors of Renovaro Inc. (RENB)
ONC - Operating profit before deduction of amortization|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage Pharma (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Inc - Income before deduction of interest, taxes and amortization|URGN (UroGen) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Corp BCAX|Profit before payment of interest, taxes and amortization Personalis, Inc. (PSNL)|ERAS (erasca.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA DCTH (Delcath Systems)|Y-mAbs Therapeutics Inc (YMAB) - Profit before interest, taxes and amortization|AURA - Profit before payment of interest, taxes and amortization|CADL (Candel Therapeutics) - Operating profit before amortization|Accuray Incorporated (ARAY) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization SELLAS Life Sciences Group (SLS)|Operating profit before deduction of amortization ACTU|Profit before payment of interest, taxes and amortization CTOR|Operating profit EBITDA HURA|Operating profit EBITDA Protara Tx (TARA)|Profit before payment of interest, taxes and amortization Fate Therapeutics, Inc. FATE|Income before deduction of interest, taxes and amortization WHWK|TCRX - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Champions Oncology|XBIT (xbiotech.com) - Operating profit before deduction of amortization|CEL-SCI - Income before deduction of interest, taxes and amortization|OSTX (OS Therapies Incorporated) - Operating profit EBITDA|radiopharmtheranostics.com (RADX) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Artiva Biotherapeutics, Inc. (ARTV)|adlainortye.com - Operating profit before amortization|Operating profit EBITDA VERU (Veru Pharma)|TPST - Operating profit before deduction of amortization|XLO: Operating profit before deduction of amortization|Operating income before deduction of amortization Mural Oncology plc MURA|kairospharma.com (KAPA) - Profit before payment of interest, taxes and amortization|OnKure Therapeutics - Income before deduction of interest, taxes and amortization|GDTC (CytoMed Therapeutics Ltd) - Operating profit EBITDA|Profit before interest, taxes and amortization Curis Corp CRIS|Profit before payment of interest, taxes and amortization Apollomics, Inc. (APLM)|tharimmune.com - Operating profit before amortization|Operating profit EBITDA ADVB (Advanced Biomed)|Genprex Inc. - Profit before payment of interest, taxes and amortization|Calidi Bio - Operating profit EBITDA|sunshinebiopharma.com (SBFM) - Operating profit before deduction of amortization|XBIO: Operating profit EBITDA|salariuspharma.com (SLRX) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Purple Biotech Ltd.|Operating profit before amortization AONC (AON)|Operating profit EBITDA BGNE|Operating profit before deduction of amortization Checkpoint Therapeutics Inc CKPT|Operating profit EBITDA ELEV (Elevation Oncology)|iCAD Inc. (ICAD) - Profit before interest, taxes and amortization|IKNA - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization NTBL (Notable Labs Ltd)|VIRX (viracta.com) - Operating profit before deduction of amortization|MorphoSys Corporation - Income before deduction of interest, taxes and amortization|NAYA (NAYA Biosciences) - Operating profit EBITDA|Operating profit before deduction of amortization ascentage.com (AAPGV)
